Keros Therapeutics (KROS) Preferred Stock Liabilities (2019 - 2020)
Keros Therapeutics' (KROS) quarterly Preferred Stock Liabilities came in at $9.1 million in Q1 2020, down 7.94% YoY from $9.9 million in Q2 2019, and down 54.34% on a QoQ basis from $19.9 million in Q4 2019.
Keros Therapeutics (KROS) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends
Keros Therapeutics (KROS) has 2 years of Preferred Stock Liabilities data on file, last reported at $9.1 million in Q1 2020.
- Quarterly Preferred Stock Liabilities fell 7.94% year-over-year to $9.1 million in Q1 2020, while the trailing twelve-month figure through Mar 2020 was $9.1 million (down 7.94% YoY) and the FY2019 annual result came in at $19.9 million, changed N/A from the prior year.
- Preferred Stock Liabilities retreated to $9.1 million in Q1 2020, from $19.9 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $19.9 million in Q4 2019 to a low of $9.1 million in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Keros Therapeutics | 217.61 Mn | -40.00 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 9.11 Mn |
| Dec 31, 2019 | 19.94 Mn |
| Sep 30, 2019 | 9.11 Mn |
| Jun 30, 2019 | 9.89 Mn |
| Mar 31, 2019 | 9.89 Mn |